Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Jan;18(1):74-9.
doi: 10.1158/1055-9965.EPI-08-0637.

Urinary melatonin levels and postmenopausal breast cancer risk in the Nurses' Health Study cohort

Eva S Schernhammer  1 , Susan E Hankinson
Affiliations

Urinary melatonin levels and postmenopausal breast cancer risk in the Nurses' Health Study cohort

Eva S Schernhammer et al. Cancer Epidemiol Biomarkers Prev. 2009 Jan.

Abstract

Background: Melatonin seems to play a role in breast cancer etiology, but data addressing the association between melatonin levels and breast cancer risk in postmenopausal women is sparse.

Methods: We conducted a nested case-control study in the Nurses' Health Study cohort. First spot morning urine was collected from 18,643 cancer-free women from March 2000 through December 2002. The concentration of the major metabolite of melatonin, 6-sulfatoxymelatonin (aMT6s), was available for 357 postmenopausal women who developed incident breast cancer through May 31, 2006, along with 533 matched control subjects. We used multivariable conditional logistic regression models to investigate associations. All statistical tests were two sided.

Results: An increased concentration of urinary aMT6s was statistically significantly associated with a lower risk of breast cancer (odds ratio for the highest versus lowest quartile of morning urinary aMT6s, 0.62; 95% confidence interval, 0.41-0.95; P(trend) = 0.004). There was no apparent modification of risk by hormone receptor status of breast tumors, age, body mass index, or smoking status.

Conclusion: Results from this prospective study add substantially to the growing literature that supports an inverse association between melatonin levels and breast cancer risk.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Smoothing spline plot for aMT6s level (ng/mg creatinine) in relation to breast cancer risk among postmenopausal women. 95% confidence intervals (CI) are indicated by dotted lines.
See this image and copyright information in PMC

References

    1. Baskett JJ, Cockrem JF, Antunovich TA. Sulphatoxymelatonin excretion in older people: relationship to plasma melatonin and renal function. J Pineal Res. 1998;24:58–61. - PubMed
    1. Graham C, Cook MR, Kavet R, Sastre A, Smith DK. Prediction of nocturnal plasma melatonin from morning urinary measures. J Pineal Res. 1998;24:230–238. - PubMed
    1. Vijayalaxmi, Thomas CR, Jr, Reiter RJ, Herman TS. Melatonin: from basic research to cancer treatment clinics. J Clin Oncol. 2002;20:2575–601. - PubMed
    1. Blask DE, Brainard GC, Dauchy RT, Hanifin JP, Davidson LK, Krause JA, Sauer LA, Rivera-Bermudez MA, Dubocovich ML, Jasser SA, Lynch DT, Rollag MD, Zalatan F. Melatonin-depleted blood from premenopausal women exposed to light at night stimulates growth of human breast cancer xenografts in nude rats. Cancer Res. 2005;65:11174–11184. - PubMed
    1. Stevens RG. Electric power use and breast cancer: a hypothesis. Am J Epidemiol. 1987;125:556–561. - PubMed

Publication types